Eptazzo
(Gemigliptin)PreclinicalSmall molecule
Gemigliptin is used to treat type 2 diabetes by helping the pancreas release more insulin and controlling blood sugar levels in patients whose blood sugar cannot be controlled by diet and exercise alone.[1] Eptazzo is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]
Eptazzo is one of 97 small molecule programs targeting Diabetic Nephropathy. It is currently in Preclinical.
4
Indications
22
Total Trials
0
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Brilinta
AstraZenecaApproved
Zyloprim
Jazz PharmaceuticalsApproved
Tracleer
Johnson & JohnsonApproved
Coreg
Akero TherapeuticsApproved
Protonix
WWyeth-Lederle Vaccines
Approved
Micardis
Boehringer IngelheimApproved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Retatrutide
Eli LillyPhase 3
Zofran
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes4 trials
Type 2 Diabetes Mellitus2 trials
Efficacy and Safety2 trials
Interaction2 trials
10 more indications
Combination Therapy1 trial
Hepatic Impairment1 trial
Calcification1 trial
Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification
Completed·—·N/A·NCT04705506·201 enrolled
Observational Study1 trial
Endothelial Function1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemigliptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]